文献速递消化系统肿瘤

Labetuzumab Govitecan(抗CEACAM5/SN-38抗体药物偶联物)在难治或复发性转移性结直肠癌患者中的I/II期试验

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2017-08-17

这项I/II期试验评估了靶向CEACAM5的抗体药物偶联物labetuzumab govitecan在既往接受过含伊立替康治疗的难治或复发性转移性结直肠癌患者中的给药方案。86例患者入组四个队列,接受每周一次8或10 mg/kg或每周两次4或6 mg/kg(原文写作mg/km)给药。单药治疗显示可控的安全性及治疗活性,每周两次给药方案因毒性及疗效相当被选为进一步研究。

要点

  • 86例经中位5线既往治疗的转移性结直肠癌患者入组四个给药队列。
  • 38%患者肿瘤及血浆癌胚抗原较基线下降,1例部分缓解持续>2年,42例最佳总体疗效为疾病稳定。
  • 中位无进展生存期3.6个月,中位总生存期6.9个月;主要≥3级毒性为中性粒细胞减少16%、白细胞减少11%、贫血9%、腹泻7%。

核心结论

  • labetuzumab govitecan单药在既往接受过含伊立替康治疗的重度经治转移性结直肠癌患者中显示出可控的安全性和治疗活性。
  • 作者认为需要进一步研究labetuzumab govitecan单药或联合其他疗法在更早期阶段中的应用。

研究设计与样本

  • I/II期扩展试验,纳入既往至少接受过一种含伊立替康治疗的难治或复发性转移性结直肠癌患者。
  • 患者接受labetuzumab govitecan每周一次8或10 mg/kg,或每周两次4或6 mg/km(原文写作mg/km),在3周重复周期的第1和第2周给药。
  • 共86例患者入组四个队列,既往治疗中位数为5线(范围1至13)。
  • 终点为安全性、缓解、药代动力学和免疫原性。

主要发现

  • 根据实体瘤疗效评价标准1.1,38%的患者在labetuzumab govitecan治疗后肿瘤及血浆癌胚抗原较基线下降。
  • 1例患者达到部分缓解,持续缓解时间>2年;42例患者最佳总体疗效为疾病稳定。
  • 中位无进展生存期为3.6个月,中位总生存期为6.9个月。
  • 所有队列中≥3级主要毒性包括中性粒细胞减少(16%)、白细胞减少(11%)、贫血(9%)和腹泻(7%)。
  • 四个队列中抗体药物偶联物的平均半衰期为16.5小时,未检测到抗药/抗抗体抗体。

关键数值与推荐

  • 38%的患者肿瘤及血浆癌胚抗原较基线下降(基于实体瘤疗效评价标准1.1)。
  • 1例部分缓解,持续缓解>2年;42例疾病稳定。
  • 中位无进展生存期3.6个月,中位总生存期6.9个月。
  • ≥3级毒性:中性粒细胞减少16%、白细胞减少11%、贫血9%、腹泻7%。
  • 平均半衰期16.5小时(四个队列),未检测到抗药/抗抗体抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or refractory metastatic colorectal cancer. Patients and Methods Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week repeated cycles. End points were safety, response, pharmacokinetics, and immunogenicity. Results Eighty-six patients who had undergone a median of five prior therapies (range, one to 13) were each enrolled into one of the four cohorts. On the basis of Response Evaluation Criteria in Solid Tumors 1.1, 38% of these patients had a tumor as well as plasma carcinoembryonic antigen reduction from baseline after labetuzumab govitecan treatment; one patient achieved a partial response with a sustained response spanning > 2 years, whereas 42 patients had stable disease as the best overall response. Median progression-free survival and overall survival were 3.6 and 6.9 months, respectively. The major toxicities (grade ≥ 3) among all cohorts were neutropenia (16%), leukopenia (11%), anemia (9%), and diarrhea (7%). The antibody-drug conjugate's mean half-life was 16.5 hours for the four cohorts. Anti-drug/anti-antibody antibodies were not detected. The two once-weekly dose schedules, showing comparable toxicity and efficacy, were chosen for further study. Conclusion Monotherapy with labetuzumab govitecan demonstrated a manageable safety profile and therapeutic activity in heavily pretreated patients with metastatic colorectal cancer, all with prior irinotecan therapy. Further studies of labetuzumab govitecan treatment alone or in combination with other therapies in earlier settings are indicated.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dotan E, Cohen SJ, Starodub AN, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017. PMID: 28817371. doi:10.1200/JCO.2017.73.9011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。